Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Fulcrum Therapeutics Inc. (FULC) Misses Q2 EPS by 17c
August 11, 2022 7:14 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.83), $0.17 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $1.88 million versus the consensus estimate of $2.96 million.
For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.
... More